TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36252412
Drug: Twice-nightly SXB
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-nightly SXB (two 3-g doses)
Study: 36252412
Drug: ON-SXB and
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON-SXB and Twice-nightly SXB
Study: 32147436
Drug: Cx32 small
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cx32 small interfering RNA and p53 inhibitor (pifithrin-α, tenovin-1)
Study: 36451052
Drug: HDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDS with OI platform (normal vs. deep randomized oral inhalation)
Study: 34455213
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 international units)
Study: 33098470
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg/30 mg once daily) plus a P2Y12 inhibitor for 12 months
Study: 33098470
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) plus a P2Y12 inhibitor and aspirin (100 mg OD, for 1–12 months)
Study: 34386935
Drug: Oral pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pioglitazone 30 mg/day (Arm A)
Study: 34799219
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid (UA) 400 mg/day
Study: 34799219
Drug: Placebo 400
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg/day
Study: 35811545
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (66 mg elemental iron daily as ferrous fumarate)
Study: 33337677
Drug: Matrix Rhythm
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix Rhythm Therapy (MRT) in addition to a combined physiotherapy program (hot pack, transcutaneous electrical nerve stimulation, therapeutic ultrasound, home exercise and patient education program)
Study: 34033974
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg/d) + Gefitinib (250 mg/d)
Study: 34033974
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Gefitinib (250 mg/d)
Study: 34048943
Drug: Nurse care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse care management focused on analgesic treatment and optimization (MED)
Study: 33210299
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral thiamine (600-1800 mg/d) for 4 weeks
Study: 33210299
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for 4 weeks
Study: 35485626
Drug: Routine training
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine training (physician's visits, medication prescriptions, recommendations from healthcare providers)
Study: 36384935
Drug: Preoperative bathing
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative bathing using plain soap among participants not given preoperative antibiotics
Study: 34609495
Drug: Deutetrabenazine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (maximum total daily dose of 48 mg/d)
Study: 32899030
Drug: Thread embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thread embedding acupuncture (TEA), 6 treatments over 6 weeks (1 time/week) on 14 defined knee areas.
Study: 32899030
Drug: Acupuncture treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment, 12 treatments over 6 weeks (2 times/week) on 9 defined acupuncture points.
Study: 36262763
Drug: Dialectical Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavioral Therapy (DBT)
Study: 35472333
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 100 mcg
Study: 33932433
Drug: Single flagellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single flagellar motor driving cell-body rotation; specific dosage and duration not mentioned.
Study: 33932433
Drug: Flagellar bundles
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flagellar bundles on glass surfaces; specific dosage and duration not mentioned.
Study: 35346849
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of intravenous tranexamic acid
Study: 35086119
Drug: Binocular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binocular treatment with Dig Rush game (1 h/d, 5 d/wk for 8 weeks)
Study: 34224363
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy after first-line chemotherapy (FL-M)
Study: 34224363
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy after platinum-sensitive recurrence (PSR-M)
Study: 34224363
Drug: Olaparib active
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib active treatment (AT)
Study: 36049498
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive statin regimens (40-80 mg atorvastatin or 20-40 mg rosuvastatin once per day)
Study: 32377159
Drug: Probiotic oral
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic oral suspension group (POSG)
Study: 32377159
Drug: Probiotic oral
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic oral suspension group (POSG) in IL-1β carriers
Study: 34274514
Drug: Obeticholic Acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic Acid 25 mg
Study: 34274514
Drug: Obeticholic Acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic Acid 10 mg
Study: 36096534
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg)
Study: 38183121
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence
Study: 34542952
Drug: Robuvit® (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robuvit® (300 mg)
Study: 33279940
Drug: Chemotherapy consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy consolidation
Study: 33645243
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus endocrine therapy
Study: 34911068
Drug: IV analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesics and intrapapillary local anesthetic infiltrations
Study: 34911068
Drug: IV analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesics
Study: 35085151
Drug: Online one-day
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online one-day workshop based on cognitive behavioral therapy
Study: 35019175
Drug: Dronedarone 400
Normalized name: dronedarone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone 400 mg twice daily
Study: 32007138
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily
Study: 34009274
Drug: anti‐IL6 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐IL6 receptor (tocilizumab, n=21)
Study: 34009274
Drug: CTLA‐4Ig treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA‐4Ig treatment
Study: 35333346
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of minor clinical symptoms (slight vaginal bleeding or some abdominal cramps) at treatment start
Study: 33181849
Drug: Propolis chewing
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis chewing gum, chewed twice daily for at least twenty minutes for two weeks
Study: 33181849
Drug: Propolis mouthwash,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis mouthwash, rinsed twice daily for one minute for two weeks
Study: 32452659
Drug: Clopidogrel hydrogen
Normalized name: Clopidogrel hydrogen sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogen sulfate tablets (75 mg) under fed conditions
Study: 32452659
Drug: Clopidogrel hydrogen
Normalized name: Clopidogrel hydrogen sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogen sulfate tablets (75 mg) under fasted conditions
Study: 32452659
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Plavix)
Study: 34717692
Drug: Concurrent ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent ibrutinib 560 mg continuously plus venetoclax ramp-up to 400 mg over 5 weeks
Study: 32636324
Drug: erenumab (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab (dose change from 140 mg to 70 mg)
Study: 32636324
Drug: erenumab (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab (dose change from 70 mg to 140 mg)
Study: 33198627
Drug: Dendrogram analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendrogram analysis of 34 individuals representing the seven L. radiata lines
Study: 34002560
Drug: Moxibustion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion combined with leflunomide tablets, applied at Sanyinjiao (SP 6), Shenshu (BL 23), Zusanli (ST 36) and ashi points, once every other day, three times a week for 8 weeks.
Study: 34002560
Drug: Leflunomide tablets
Normalized name: Leflunomide Tablets
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide tablets taken orally, once a day for 8 weeks.
Study: 34237553
Drug: Animal Assisted
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal Assisted Therapy (AAT)
Study: 34128766
Drug: Measles Containing
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles Containing Vaccines (MCVs)
Study: 33053116
Drug: G‐CSF (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (granulocyte colony‐stimulating factor)
Study: 32097252
Drug: ART delivered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART delivered three-monthly in CARGs (3MC)
Study: 32097252
Drug: ART delivered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART delivered six-monthly in CARGs (6MC)
Study: 32097252
Drug: ART collected
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART collected three-monthly at facility (3MF)
Study: 36370907
Drug: Ritlecitinib 50
Normalized name: ritlecitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 50 mg with loading dose
Study: 36370907
Drug: Ritlecitinib 50
Normalized name: ritlecitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 50 mg without loading dose
Study: 37707764
Drug: Ritlecitinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 30 mg
Study: 36370907
Drug: Ritlecitinib 200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 200/50 mg in extension period
Study: 33826641
Drug: Agent-based model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent-based model with refined parameter estimation methods
Study: 36436883
Drug: BLI/WBT (Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI/WBT (Behavioral Lifestyle Intervention followed by Well-Being Therapy)
Study: 33579265
Drug: Atractylodes lancea
Normalized name: Atractylodes Lancea Root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atractylodes lancea extract (AL) at a single oral dose of 1000 mg
Study: 33579265
Drug: Atractylodes lancea
Normalized name: Atractylodes Lancea Root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atractylodes lancea extract (AL) at multiple dosing of 1000 mg for 21 days
Study: 32243274
Drug: 19 G
Normalized name: Sharps Collector 19 Gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 G EBUS needle
Study: 32243274
Drug: 21 G
Normalized name: Long's Lancets, 21 ga
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 G EBUS needle
Study: 34423649
Drug: Ticagrelor pooled
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor pooled (60 or 90 mg BID)
Study: 34155568
Drug: Brivaracetam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 200 mg/day
Study: 32021219
Drug: Personal Construct
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal Construct Therapy (PCT)
Study: 32747190
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with pemetrexed plus cisplatin along with EGFR-TKI
Study: 32747190
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with EGFR-TKI followed by chemotherapy after progression
Study: 35253334
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg/day
Study: 33020134
Drug: Hypoglycemia (HypoEx)
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (HypoEx) with blood glucose (BG)≤3.9 mmol/L
Study: 33020134
Drug: Euglycemia (EuEx)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (EuEx) with BG≥4.0, BG≤10.0 mmol/L
Study: 34606988
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy duration (2 weeks vs. 8 weeks)
Study: 37149056
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus placebo
Study: 34774197
Drug: ChAdOx1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 plus cellular quadrivalent influenza vaccine
Study: 34774197
Drug: BNT162b2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 plus cellular quadrivalent influenza vaccine
Study: 34774197
Drug: BNT162b2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 plus MF59C adjuvanted, trivalent influenza vaccine
Study: 34774197
Drug: ChAdOx1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 plus recombinant quadrivalent influenza vaccine
Study: 34774197
Drug: ChAdOx1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 plus MF59C adjuvanted, trivalent influenza vaccine
Study: 34774197
Drug: BNT162b2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 plus recombinant quadrivalent influenza vaccine
Study: 34774197
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of COVID-19 and influenza vaccines
Study: 34774197
Drug: Concomitant vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine
Study: 32820000
Drug: Leucocyte-rich PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-rich PRP (LR-PRP) injection
Study: 32089371
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training based on international physical activity recommendations (PAR group)
Study: 35297659
Drug: LT3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LT3 treatment (0.8 μg/kg i.v. bolus followed by 0.113 μg/kg/h i.v. infusion for 48 hours)
Study: 35572853
Drug: LT3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LT3 treatment
Study: 33796965
Drug: Compound topical
Normalized name: benzoin compound TOPICAL TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound topical anesthetic (CTA) combined with photobiomodulation therapy (PBMT)
Study: 32729014
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate (TDF) 245 mg/day
Study: 32151227
Drug: Inorganic nitrate
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrate drink (140-ml beetroot juice per day)
Study: 34972894
Drug: Pythagorean Self‐Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pythagorean Self‐Awareness Intervention (PSAI) for 8 weeks along with continuous positive airway pressure (CPAP) treatment
Study: 34972894
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment alone
Study: 33674871
Drug: ALB 400
Normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALB 400 mg
Study: 33674871
Drug: ALB 800
Normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALB 800 mg
Study: 33232804
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily)
Study: 35620986
Drug: Oral bicarbonate
Normalized name: sodium bicarbonate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bicarbonate (n=78)
Study: 35620986
Drug: Intravenous bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bicarbonate (n=82)
Study: 34033648
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg QD for 7 to 10 days
Study: 34033648
Drug: Methylprednisolone 250
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 250 to 500 mg daily for 3 days followed by oral prednisone 50 mg daily for 14 days
Study: 35699377
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy
Study: 32331053
Drug: Placebo (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (adjunctive therapy)
Study: 32331053
Drug: Adjunctive lurasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive lurasidone (recurrence prevention study)
Study: 32331053
Drug: Adjunctive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive placebo (recurrence prevention study)
Study: 34168425
Drug: Cold intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold intraoperative irrigating solution (2.7±0.1°C)
Study: 34168425
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigating solution (20.0±0.1°C)
Study: 35491738
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin
Study: 33881605
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment followed by skin surface application of a cosmeceutical containing growth factors (GFs) and Vitamin C
Study: 32471651
Drug: Overall randomised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall randomised controlled trials in oral and maxillofacial surgery
Study: 35964661
Drug: Delivery room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery room insertion of etonogestrel contraceptive implant (0-2 hours post-delivery)
Study: 35964661
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of etonogestrel contraceptive implant (24-48 hours post-delivery)
Study: 35964661
Drug: Delivery room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery room insertion of etonogestrel contraceptive implant
Study: 35964661
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of etonogestrel contraceptive implant
Study: 34726708
Drug: Lower-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose amoxicillin (35-50 mg/kg/d)
Study: 34726708
Drug: Higher-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose amoxicillin (70-90 mg/kg/d)
Study: 34726708
Drug: Lower-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose amoxicillin in severe CAP
Study: 34726708
Drug: Higher-dose amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose amoxicillin in severe CAP
Study: 34726708
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment in severe CAP
Study: 34726708
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment in severe CAP
Study: 35381377
Drug: Weekly shipments
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly shipments of five breakfast and lunch meals that mimic school meals
Study: 35381377
Drug: Weekly newsletter
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly newsletter on community resources
Study: 35089373
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 50 mg
Study: 35089373
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 200 mg
Study: 34753843
Drug: Mini implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini implants
Study: 32113628
Drug: Adjuvanted RSV
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted RSV vaccine